Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > NASH Protocol News Tomorrow?

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on May 19, 2021 4:42pm

111 Views

Post# 33231900

RE:RE:NASH Protocol News Tomorrow?

That was related to the earlier post.

scarlet1967 wrote: It clearly states in the sec document that THTX will have to pay for IM. So even if company wanted to bypass that trial they would have needed Taimed's approval. I don't see why even go with IV push it might be faster but still an IV administration now IM is clearly much more convenient so it should be easier to start patient on it and better compliance.
I just hope as you stated it will be worth the cost.

SPCEO1 wrote: THTX will be having its fireside chat tomorrow with Canaccord at 2PM but I believe they also rescheduled an earlier call with NBF brokers until tomorrow at Noon. Could that rescheduling indicate we will get some news tomorrow? If so, I would guess it would be the finalized NASH phase III protocol since the meeting with the FDA about that likely took place some weeks ago and THTX was simply waiting for the official letter to arrive from the FDA before making any announcement. From what I recall, those letters typically are sent 30 days after the meeting and summarize the conclusion of the meeting. So, THTX already likely knows the outcome of the NASH protocol meeting with the FDA but has had to sit on it until the letter arrived - this is probably why Paul stated with great confidence that the NASH trial would get started in Q3.

That is my best guess. But it also may simply be informational meetings tommorrow with no news associated with it. We will know soon enough. I am hoping LSA will help them in leveraging such events with good news, however,